RxDoctor Payments Data

Mark Goralewski, MD

Dermatology · Livonia, MINPI 1013395961

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by AbbVie at 48.8% of the total. Among dermatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,978in general payments, 2019–2025

Across 1,111 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Johnson & Johnson$3K
  • Sun Pharmaceutical Industries Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Novartis$1K
  • Sanofi$1K
  • plus $8K from 37 others

What the payments were for

  • Consulting fees$9503%
  • Speaking & faculty fees$13,31339%
  • Food & beverage$18,75655%
  • Education$9603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,978 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$292,398
Medicare patients
904
Services billed
6,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab135$492,827
SkyriziRisankizumab-Rzaa17$330,497
Taltz AutoinjectorIxekizumab33$222,784
OtezlaApremilast40$190,073
Dupixent SyringeDupilumab48$176,790
Humira(Cf) PenAdalimumab15$109,161
Ketoconazole425$7,968
Clobetasol Propionate191$5,998
Triamcinolone Acetonide600$5,848
Fluocinonide128$4,583
Metronidazole78$3,208
Betamethasone Dipropionate71$2,524
Calcipotriene16$2,411
Tacrolimus15$2,304
Clindamycin Phosphate117$2,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$16,598$330,49717 claims
AmgenOtezla$907$190,07340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.

Other dermatology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →